A Randomized, Double-Blind, Placebo Controlled, Phase 3, Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis
收藏DataCite Commons2025-06-23 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00005692/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The objectives of this study are to assess the safety and efficacy of treatment with pirfenidone 2403 milligrams per day (mg/d) compared with placebo in patients with idiopathic pulmonary fibrosis (IPF), to assess the safety and efficacy of treatment with pirfenidone 1197 mg/d in patients with idiopathic pulmonary fibrosis and to characterize the pharmacokinetic disposition of pirfenidone in patients with idiopathic pulmonary fibrosis.
提供机构：
Vivli
创建时间：
2020-05-05
